Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1400 | Enoxaparin Higher Dose Wiki | 1.00 |
| drug4583 | mobile internet survey on self-test Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009164 | Mycobacterium Infections NIH | 0.50 |
| D004198 | Disease Susceptibility NIH | 0.45 |
| D003141 | Communicable Diseases NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a randomized open label trial to compare effectiveness of two dosing regimens currently used for prevention of clotting events in COVID-19 positive inpatients. Both doses and routes of anticoagulation regimens are currently used in COVID-19 positive inpatients at NYU Langone Health.
Description: 0 = Uninfected; no viral RNA detected Ambulatory = Asymptomatic; viral RNA detected = Symptomatic: Independent = Symptomatic: assistance needed Hospitalized: Mild disease = Hospitalized; no oxygen therapy = Hospitalized; oxygen by mask or nasal prongs = Hospitalized; oxygen by NIV or High flow = Intubation & Mechanical ventilation, pO2/FIO2 >/= 150 or SpO2/FIO2 = Mechanical ventilation pO2/FIO2 < 150 (SpO2/FIO2 <200) 9 = Mechanical ventilation pO2/FIO2 < 150 and vasopressors, dialysis 10 = Dead N (%)
Measure: Score on WHO Ordinal Scale Time: 30 daysDescription: AKI is defined as any of the following (Not Graded): Increase in SCr by X0.3 mg/dl (X26.5 lmol/l) within 48 hours; or Increase in SCr to X1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or- Urine volume o0.5 ml/kg/h for 6 hours.
Measure: Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI)) Time: 30 daysDescription: Measured by troponin and NTproBNPlevels
Measure: Cardiac injury Time: 30 daysDescription: measured by D-dimer and fibrinogen levels
Measure: Hypercoagulability Time: 30 daysDescription: Platelet Count >100 x 109/L 0 Points >50 - <100 x 109/L 1 Point <50 x 109/L 2 Points Increase in Fibrin-related Markers [D Dimers] No change 0 Points Moderate rise 2 Points Strong rise 3 Points Prothrombin Time [PT] Prolongation 3 s or less 0 Points >3 s but <6 s 1 Point >6 s 2 Points Fibrinogen [Clauss] Level >1.0 g/L 0 Points <1.0 g/L 1 Point Score 0-8 Interpretation of Score < 5 Suggestive of non-overt/low grade DIC. Repeat in 1-2 days. ≥ 5 Laboratory evidence consistent with overt DIC.
Measure: Disseminated Intravascular Coagulation (DIC) Score Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports